
ILIAS Biologics Publishes Phase 1 Clinical Trial Results of ILB-202 in JEV
First-in-human study of a systemically administered anti-inflammatory engineered exosome therapy highlights its clinical potential and commercial viability SEOUL, EUNPYEONG, SOUTH KOREA, September 28, 2025 /EINPresswire.com/ -- ILIAS Biologics Inc. ( …